Trefoil Therapeutics

Trefoil Therapeutics is a clinical-stage biotechnology company focused on leveraging its engineered FGF-1 compound protein technology platform to develop first-in-class therapeutic treatments for serious corneal endothelial diseases and epithelial conditions. Trefoil's lead candidate is TTHX1114, an engineered form of naturally occurring FGF-1 designed to stimulate corneal endothelial cell proliferation and migration, thereby reversing vision loss caused by CED. The technology behind Trefoil’s platform was developed by co-founder Dr. Michael Blaber and licensed from Florida State University. TTHX1114 has the potential to become the first drug treatment for corneal endothelial dystrophy (the leading cause of corneal transplantation). Trefoil’s second development program focuses on a TTHX1114 eye drop formulation for treating ulcers on the anterior surface of the cornea, a condition that can lead to corneal scarring and severe vision loss.